The observation of increasing Replikin Counts provides time to prepare an optimal public health response, time to prepare vaccines and other therapies specific to the oncoming organism, in sufficient quantity, and time to adequately test and distribute the vaccine before the hit-and-run outbreak has begun to disappear as happened in 2009.

In addition, the new Replikins synthetic vaccines provide distinct advantages over traditional vaccines. They are tailored to the specific Replikins in the current threatening organism, solid-phase synthesized completely free of biologicals, thus containing no bio-contaminants, synthesized in seven days instead of eight months, and effective when shipped freeze-dried, not requiring refrigeration, and at an estimated cost for seven billion people of 10 cents per person compared with the cost of $14 per person for the biological vaccines purchased for the 2009 influenza pandemic (USA GAO).

The Replikins data suggests that any vaccines, which might be active against H5N1 (such as synthetic Replikin Trans FluVaccine 2012) and against the SARS-like virus (such as synthetic Replikin Vaccine SARS 2012), should be produced and tested as soon as possible. For these reasons, the company Replikins is announcing that both of these vaccines are now available for testing by government health agencies and medical schools.